Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Australia ETF (EWA) vs Cassava Sciences Inc (FLNA) Price & Performance

iShares MSCI Australia ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Australia ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Australia ETF trades at $28.59, while Cassava Sciences Inc trades at $1.06 (market cap $53.14M). The key difference: iShares MSCI Australia ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

EWAFLNA
Sector
Broad Market / FactorHealth
52-Week High
$30.26$4.64
52-Week Low
$24.95$1.09
Market Cap
$53.14M
Enterprise Value
-$33.43M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Australia ETF

EWA trades at $28.625, down 0.3% with a bullish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 72.02 suggesting potential overbought conditions. Recent news highlights Australia's economic developments including fuel excise relief and tax reforms that may impact investor sentiment toward Australian-focused assets.

The outlook remains cautiously optimistic given the bullish technical setup, though limited fundamental data availability requires careful monitoring. Key risks include Australian economic sensitivity and market volatility from geopolitical tensions. Investors should await updated financial metrics for comprehensive fundamental assessment.

Cassava Sciences Inc

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Australia ETF

EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.

Read more on EWA

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA